Compile Data Set for Download or QSAR
Report error Found 324 Enz. Inhib. hit(s) with all data for entry = 79
TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160829(US9682976, 102 | US9682976, 1)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160830(US9682976, 2)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160831(US9682976, 3)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160833(US9682976, 4)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160834(US9682976, 5)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160835(US9682976, 6)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160836(US9682976, 7)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160837(US9682976, 8)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160838(US9682976, 9)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160839(US9682976, 10)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160840(US9682976, 11)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160842(US9682976, 12)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160843(US9682976, 13)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160845(US9682976, 14)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160847(US9682976, 15)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160848(US9682976, 16)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161048(US9682976, 17)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161049(US9682976, 18)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161053(US9682976, 19)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161054(US9682976, 21 | US9682976, 20)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161054(US9682976, 21 | US9682976, 20)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161068(US9682976, 22)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161069(US9682976, 23)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161070(US9682976, 24)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161071(US9682976, 25)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161072(US9682976, 26)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161073(US9682976, 29 | US9682976, 27)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161074(US9682976, 28)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161073(US9682976, 29 | US9682976, 27)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161076(US9682976, 30)
Affinity DataEC50: >1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161077(US9682976, 31)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161078(US9682976, 32)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161079(US9682976, 33)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161080(US9682976, 34)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161081(US9682976, 35)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161082(US9682976, 36)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161083(US9682976, 37)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161084(US9682976, 38)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161086(US9682976, 39)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161100(US9682976, 40)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161107(US9682976, 41)
Affinity DataEC50: <500nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161123(US9682976, 42)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161125(US9682976, 43)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161144(US9682976, 44)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161159(US9682976, 45)
Affinity DataEC50: <1.00E+4nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161160(US9682976, 46)
Affinity DataEC50: <1.00E+3nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161161(US9682976, 50 | US9682976, 47)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161162(US9682976, 48)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161163(US9682976, 49)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161161(US9682976, 50 | US9682976, 47)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 324 total ) | Next | Last >>
Jump to: